While first reports indicated the successful use of anti-IL-6 drugs for the treatment of COVID-19 (74), two randomized studies (one with tocilizumab and the other with sarilumab) failed to demonstrate the positive effects of the aforementioned treatment (75). The gene discussed is IL6; the disease is COVID-19.